NCT07528911Completed
Elements of Adaptive Immunity in Epithelial Ovarian Cancer
Prognostic Significance of Adaptive Immunity Cell Infiltrates in the Microenvironment of High-grade Serous Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 687 (actual)
- First submitted
- 23 Jul 2025
- Start date
- Apr 2023
- Primary completion date
- Apr 2025
- Lead sponsor
- Hellenic Cooperative Oncology Group
- Diseases
- Ovarian cancer, Childhood cancers
- NCT number
- NCT07528911
What you commit to
- Study type: Observational
- Participants enrolled: 687
- From Apr 2023 to the primary completion date, Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any other histology than high grade ovarian cancer
Other
- Patients with stages I-II (based on FIGO staging)
Who the study is looking for
- Patients with advanced high grade serous ovarian cancer treated with carboplatin/paclitaxel chemotherapy
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hellenic Cooperative Oncology Group Coordinator of this site? Confirm its status | Athens | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.